A EFFACER

systematic review meta-analysis network meta-analysis

Select melanoma adjuvant setting       anti-CTLA-4anti-PD-1BRAF inhibitorcombined BRAF and MEK inhibitioninterferon Interferon alphatrametinib + dabrafenib vemurafenibipilimumabnivolumabpembrolizumab vs anti-CTLA-4vs placebo or control       adjuvant

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (9)death (overall survival) (7)Grade 3–5 drug-related AEs (3)recurrence free survival (3)distant metastasis free survival (3)vitiligo any grade (1)vitiligo grade 3-4 (1)Adverse events leading to treatment discontinuation (1)aaa (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)	death (overall survival)
melanoma
Interferon alpha
EORTC18952 (Eggermont), 2005	ID IFN alpha-2b (I M)	observation	adjuvant			negative
Nordic IFN Trial, 2011	ID IFN alpha-2b (I M)	observation	adjuvant			suggesting
EORTC18991 (Eggermont), 2008	PEG IFN alpha-2b (I M)	observation	adjuvant			suggesting
EORTC18871/DKG 80-1 (Kleeberg), 2004	rIFN alpha-2b	observation	adjuvant			negative
ipilimumab
EORTC 18071 (Eggermont), 2015        NCT	ipilimumab	placebo	adjuvant	adjuvant	Low risk of bias	conclusive
nivolumab
CheckMate 238, 2017      NCT	nivolumab	ipilimumab	adjuvant	adjuvant	Low risk of bias	conclusive
pembrolizumab
KEYNOTE-054, 2018      NCT	pembrolizumab	placebo	adjuvant	adjuvant	Low risk of bias	conclusive
trametinib + dabrafenib
COMBI-AD, 2017      NCT	trametinib and dabrafenib	placebo	adjuvant		Low risk of bias	suggesting
COMBI neo, 2018      NCT	trametinib and dabrafenib	SOC	adjuvant			-
vemurafenib
BRIM 8, 2018      NCT	vemurafenib	placebo	adjuvant			suggesting